By PR Newswire, October 23, 2013, 08:00:00 AM EDT
NEW YORK, October 23, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), Chemed Corp. (NYSE:CHE), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Immunomedics Inc. (NASDAQ:IMMU), and Sangamo Biosciences Inc. (NASDAQ:SGMO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Vanda Pharmaceuticals, Inc. Research Report
On October 16, 2013, Vanda Pharmaceuticals, Inc. (Vanda) announced that it has been notified by the US Food and Drug Administration (FDA) about the scheduling of a Peripheral and Central Nervous System Drugs Advisory Committee meeting to be held on November 14, 2013, which will focus on reviewing the Company's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. The Company reported that tasimelteon NDA is currently under Priority Review by the FDA with an action target date under the Prescription Drug User Fee Act (PDUFA-V) of January 31, 2014. The Full Research Report on Vanda Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b5ad_VNDA]
Chemed Corp. Research Report
On October 1, 2013, Chemed Corp. (Chemed) announced that it will release its Q3 2013 results after the close of trading on NYSE on Monday, October 28, 2013. Chemed stated that it will discuss its results in a conference call and webcast on Tuesday, October 29, 2013 at 10:00 a.m. ET. The Company informed that the webcast and its replay can be accessed through the Investor Relations section of its website. The Full Research Report on Chemed Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4c0d_CHE]
Portola Pharmaceuticals, Inc. Research Report
On October 17, 2013, Portola Pharmaceuticals, Inc. (Portola) announced the pricing of its underwritten public offering of c.6.4 million shares of its common stock at a price of $23.75 per share to the public. Portola reported that it is offering c.4.5 million shares of common stock, and certain existing stockholders of Portola are offering c.1.9 million shares of common stock. The Company stated that it will not receive proceeds from the sale of shares by the selling stockholders, and the underwriters of the offering have been granted a 30-day option to purchase up to an additional approximately 1 million shares from Portola at the public offering price. Portola further notified that the offering is expected to close on October 22, 2013, subject to customary closing conditions. The Full Research Report on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/102f_PTLA]
Immunomedics Inc. Research Report
October 9, 2013, Immunomedics Inc. (Immunomedics) announced that it has received notification from Takeda Pharmaceutical Company regarding the termination of the licensing agreement signed between Nycomed GmbH and Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, for all non-cancer indications. Immunomedics further stated that the notification was received after the Company filed for arbitration proceedings in order to resolve the dispute with Nycomed concerning delays in the development of veltuzumab, which Immunomedics argues is a material breach of the licensing agreement. Immunomedics reported that due to termination of the agreement, all rights to veltuzumab revert to the Company and both parties have begun discussions regarding the transition of veltuzumab back to the Company. The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c20d_IMMU]
Sangamo Biosciences Inc. Research Report
On October 16, 2013, Sangamo Biosciences Inc. (Sangamo) announced that it will release its Q3 2013 results after the market close on Wednesday, October 23, 2013. Sangamo stated that after issuing the press release, it will host a conference call on the same day at 5:00 p.m. ET to review the financial results, which can be accessed via telephone and webcast. The Company informed that live webcast can be accessed through its Investor Relations website, and the conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 23, 2013 to 11:59 p.m. ET on October 30, 2013. The Full Research Report on Sangamo Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/52a6_SGMO]
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner